Ascentage Pharma's Olverembatinib Shows 91.3% CCyR, 60.9% MMR in CML-CP
Ascentage Pharma announced updated efficacy and safety data for its first approved product, olverembatinib, as a second-line therapy for chronic-phase chronic myeloid leukemia (CML-CP) at the 2026 ASCO Annual Meeting. The data showed a complete cytogenetic response (CCyR) rate of 91.3% and a major molecular response (MMR) rate of 60.9% at cycle 24, with responses deepening over time. Olverembatinib demonstrated a stable and manageable safety profile, further supporting its potential as a second-line treatment option. The company is also conducting three global registrational Phase III studies for olverembatinib and has an exclusive option agreement with Takeda for global rights outside certain territories.
Key Highlights
- Olverembatinib data presented at 2026 ASCO Annual Meeting.
- Achieved 91.3% complete cytogenetic response (CCyR) at cycle 24 in CML-CP.
- Achieved 60.9% major molecular response (MMR) at cycle 24 in CML-CP.
- Best CCyR rate of 76.2% and best MMR rate of 47.6% at study cutoff.
- Overall incidence of treatment-related adverse events was 89.4%.
- Ascentage Pharma's 9th consecutive appearance at ASCO.
- Six studies involving three key assets selected for presentation at ASCO.
Price Impact
More from AAPG